Dr. Reddy's Laboratories Limited (RDY) Stock Price & Analysis
Dr. Reddy's Laboratories Limited (RDY) closed at USD 13.21 on Friday, October 23, 2026, down 0.15% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.23; the Oct 23, 2026 session ranged USD 13.18–13.55 on volume of 3,909,234 shares. Market capitalization is $11.00B, with a 52-week range of USD 11.36–15.67 (NYQ). Source: Nexqual, retrieved October 24, 2026 at 05:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RDY.md
Key facts (RDY)
- Analysts: Buy (mean 2.40 on a 1–5 scale) (5 analysts), mean target USD 13.78 (range 11.45–15.52).
- Total return with dividends: 1Y -8.8% vs S&P 500 +13.4%; 5Y +12.8% vs S&P 500 +76.9%.
- Next earnings: 2026-10-23, EPS estimate USD —, revenue estimate $93.1B.
Analysts (RDY)
Consensus Buy (mean 2.40 on a 1–5 scale), 5 analysts; mean target USD 13.78 (low 11.45, high 15.52).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Citigroup | Upgrade | Sell → Buy | $1040 → $1450 |
Total return (dividends reinvested) (RDY)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -8.8% | +12.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -8.8% | +2.5% |
| Volatility (annualized) | 27.7% | 23.9% |
| Max drawdown | -26.0% (Jun 2026→Jul 2026) | -28.8% (Aug 2024→Jul 2026) |
RDY suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | United Healthcare Services | “We support our local customers through our commercial offices in various markets, including Brazil, China, Europe, India, Japan, Mexico, the United States, United Arab Emirates and Russia with colleagues from regulatory affairs and commercial.” |
| Customer | India | “We support our local customers through our commercial offices in various markets, including Brazil, China, Europe, India, Japan, Mexico, the United States, United Arab Emirates and Russia with colleagues from regulatory affairs and commercial.” |
| Partner | Kunshan Rotam Reddy Pharmaceuticals Company | “Over the past several years, our joint venture called Kunshan Rotam Reddy Pharmaceuticals Company Limited ("KRRP") has commercialized several products.” |
| Partner | Aurigene Pharmaceutical Services | “As part of his role, he heads our API business, the Aurigene Pharmaceutical Services Limited ("APSL") business, public health initiatives and business-to-business collaborations for our company.” |
| Partner | Amazon (AMZN) | “He also played a critical role in driving various new growth initiatives, including the acquisition of over-the-counter brands; the development of our e-commerce presence on Amazon; and engaging with alternate channel partners.” |
| Partner | Haleon UK Enterprises | “For the limited markets still under transition, we continue to obtain distribution and related services under a Transitional Distribution Services Agreement with the Haleon Group until the remaining transfers are completed.” |
| Partner | Journey Medical Corp (DERM) | “For the year ended March 31, 2025, the license fees includes an amount of Rs.1,266 (U.S.$15) as a milestone payment receivable upon U.S. FDA approval of DFD 29, in accordance with the license and collaboration agreement dated June 29, 2021 with Journey Medical Corporation.” |
| Competitor | Lonza | “Key competitors in India include Syngene International Ltd., Aragen Life Sciences, Sai Life Sciences and Piramal Pharma Ltd. Key competitors from outside India include Lonza Group, Patheon Inc., Catalent Inc., Cambrex Inc., and WuXi Apptec.” |
| Competitor | WuXi | “Key competitors in India include Syngene International Ltd., Aragen Life Sciences, Sai Life Sciences and Piramal Pharma Ltd. Key competitors from outside India include Lonza Group, Patheon Inc., Catalent Inc., Cambrex Inc., and WuXi Apptec.” |
Quoted from the company's 20-F filed May 29, 2026.
RDY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | — | — | — | $93.09B | — |
| Next quarter (ends Mar 2027) | — | — | — | $94.33B | — |
| Current fiscal year (ends Mar 2027) | $46.22 | $43.85 | +5.4% | $354.04B | 2 |
| Next fiscal year (ends Mar 2028) | $62.49 | $62.08 | +0.7% | $393.23B | 2 |
Key Statistics (as of October 24, 2026 at 05:04 UTC)
| Price | USD 13.21 |
|---|---|
| Change | ▼ 0.15% (down) |
| Previous Close | USD 13.23 |
| Open | USD 13.52 |
| Day Range | USD 13.18 – 13.55 |
| 52-Week Range | USD 11.36 – 15.67 |
| Volume | 3,909,234 shares |
| Market Cap | $11.00B |
| Exchange | NYQ |
Technical Analysis (RDY)
Nexqual's technical model rates RDY "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 24, 2026 at 05:04 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.6 (neutral) |
| vs SMA50 | Above (USD 12.36) |
| MACD | 0.26 (positive) |
Analyst Ratings (RDY)
Wall Street analysts rate RDY "Buy" based on 5 analysts, with a mean price target of USD 13.78 (range USD 11.45–15.52), per Nexqual as of October 24, 2026 at 05:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 13.78 |
| High Target | USD 15.52 |
| Low Target | USD 11.45 |
| Buy / Hold / Sell | 3 / 1 / 1 |
Earnings (RDY)
| Next Earnings Date | 2026-10-23 |
|---|---|
| Revenue Estimate | $93.09B |
Source: Nexqual, October 24, 2026 at 05:04 UTC.
Financials & Fundamentals (RDY)
| Total Revenue | $331.19B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -5.60% |
| Gross Margin | +50.18% |
| Operating Margin | +4.25% |
| Profit Margin | +10.00% |
| ROE | +8.84% |
| Debt / Equity | 0.19 |
| Current Ratio | 1.9 |
| Total Cash | $81.43B |
| Total Debt | $71.95B |
Source: Nexqual, October 24, 2026 at 05:04 UTC.
Financial Health Score (RDY)
Nexqual rates Dr. Reddy's Laboratories Limited's overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 05:04 UTC.
| Growth | Mixed — Revenue +3.2% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 50%, operating 4% (last 12 months) |
| Balance Sheet | Strong — INR 81.4B cash vs INR 72.0B debt, net cash position |
| Cash Flow | Solid — Operating cash flow INR 41.2B (TTM) |
| Efficiency | Mixed — ROE 9%, ROA 4.0% |
Ownership (RDY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +14.89% |
| Shares Outstanding | 833.07M |
| Float | 3.59B |
| Short % of Float | +4.14% |
Source: Nexqual, October 24, 2026 at 05:04 UTC.
Leadership (RDY)
Dr. Reddy's Laboratories Limited is led by Erez Israeli, CEO & Member of the Management Council, per Nexqual as of October 24, 2026 at 05:04 UTC.
| CEO & Member of the Management Council | Erez Israeli |
|---|---|
| Co-Chairman, MD & Member of Management Council | Gunupati Venkateswara Prasad B.E. |
| Chairman of the Board & Member of the Management Council | Kallam Satish Reddy B.Tech., M.S. |
| CFO & Member of the Management Council | Mannam Venkatanarasimham |
| Executive VP, COO & Member of Management Council | Sanjay Sharma B.Tech. |
Major Backers & Investors (RDY)
Notable institutional backers of Dr. Reddy's Laboratories Limited include Morgan Stanley, Royal Bank of Canada, Robeco Institutional Asset Management B.V., according to Nexqual as of October 24, 2026 at 05:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 1.31% |
| Royal Bank of Canada | 1.1% |
| Robeco Institutional Asset Management B.V. | 1.04% |
| Aikya Investment Management Ltd | 1.02% |
| Renaissance Technologies | 0.88% |
| JPMorgan | 0.49% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.27% |
| Dimensional Fund Advisors | 0.64% |
| State Street | 0.49% |
| Vanguard Group | 0.48% |
Source: Nexqual, October 24, 2026 at 05:04 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELAN | Elanco Animal Health Incorporat | USD 22.52 | ▼ 0.75% |
| NBIX | Neurocrine Biosciences, Inc. | USD 142.7 | ▼ 0.41% |
| ALKS | Alkermes plc | USD 43.63 | ▼ 1.24% |
| AMRX | Amneal Pharmaceuticals, Inc. | USD 20.38 | ▼ 0.49% |
| HIMS | Hims & Hers Health, Inc. | USD 27.71 | ▼ 4.87% |
| LNTH | Lantheus Holdings, Inc. | USD 99.8 | ▼ 0.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 05:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt